Evidence map›Paper›PMID 30107173›Full record

ArticleCancer cell2018

Pulling a MAST1 on Cisplatin Resistance.

Ankita B Jaykumar, Aroon S Karra, Melanie H Cobb

Open access · bronzeAbstract readComment
PubMed Publisher
In one paragraph

Article in Cancer cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ankita B JaykumarDepartment of Pharmacology, UT Southwestern Medical Center, Dallas, TX 75390, USA.
Aroon S KarraDepartment of Pharmacology, UT Southwestern Medical Center, Dallas, TX 75390, USA.
Melanie H CobbDepartment of Pharmacology, UT Southwestern Medical Center, Dallas, TX 75390, USA. Electronic address: melanie.cobb@utsouthwestern.edu.
Southwestern Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this issue of Cancer Cell, Jin and colleagues use a kinome-wide screen to identify MAST1 as a cause of cisplatin resistance. They demonstrate that this kinase is a novel activator of MEK1 and the MAPK cascade and that it can harness pathway output to block cisplatin-induced cell death.

Indexed as

Antineoplastic AgentsCisplatinDrug Resistance, NeoplasmHumansMAP Kinase Signaling SystemProtein Serine-Threonine KinasesAntineoplastic AgentsCisplatinProtein Serine-Threonine Kinases

Identifiers

PMID30107173
OpenAlexW2887326809

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.